PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

MERXIN LTD IS INCREDIBLY HONOURED TO RECEIVE A KING’S AWARD FOR ENTERPRISE FOR INNOVATION.

Merxin Ltd has been honoured with a King’s Award for Enterprise for Innovation.

Merxin Ltd is one of only 185 organisations nationally to be recognised with a prestigious King’s Award for Enterprise in 2026. Announced today (Wednesday 6 May at 1pm in the Royal Gazette). The Award acknowledges the company’s outstanding achievement in Innovation.

Employing 21 people, Merxin Ltd is a biotech company founded in 2015 and based in King’s Lynn, Norfolk, U.K.. The company designs and supplies devices for inhaled therapies.

Their innovation, MRX004, is a soft mist inhaler enabling precision drug delivery whilst minimising environmental impact. The global soft mist inhaler market has long been dominated by proprietary devices, limiting pharmaceutical companies’ options, raising treatment costs, and restricting patient access. Current inhalers have either low performance or high environmental impact. MRX004 addresses these shortcomings through a variable-dose firing mechanism, optimised aerosolisation options for improved respiratory tract delivery, and a design engineered for low global warming potential. Multiple patents protect the innovation.

Commercial contracts have been secured with blue chips companies in Europe and in the United States, with further growth anticipated from 2027.

“This Award is a proud moment for everyone at Merxin Ltd and a testament to ten years of outstanding innovation by an exceptional team. Graham and I are deeply honoured by the recognition from His Majesty The King and the Prime Minister. We are excited about what this milestone means for our future.” said Philippe Rogueda, Chief Business Officer and co-founder.

To Learn More about Merxin Ltd visit: https://www.merxin.com

Contact: Philippe Rogueda, CBO; (44) 01553 403070, philippe@merxin.com

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026